Literature DB >> 8736222

Sites of disease action in a retinal dystrophy with supernormal and delayed rod electroretinogram b-waves.

D C Hood1, A V Cideciyan, D A Halevy, S G Jacobson.   

Abstract

Delayed rod ERG b-waves in patients with an unusual retinal dystrophy have been attributed by some to an abnormality in receptor cGMP activity. Here the sites of disease action are studied by analyzing rod and cone ERGs using new analytical methods and a wide range of stimulus intensities. Consistent with previous reports, the five patients studied showed rod b-waves that were normal or supernormal in amplitude in response to intense flashes, but smaller than normal and markedly delayed in response to weaker flashes. The cone ERGs, recorded to 29 Hz flicker and to flashes upon a background, were smaller than normal and also showed delays. Models of phototransduction fitted to rod and cone a-waves indicated that the delays in the rod and cone b-waves were not due to the speed or amplification of the transduction process. An analysis of the derived inner nuclear layer (INL) response suggests that the sites of disease action are beyond the outer segment and involve a delay in the activation of INL activity.

Entities:  

Mesh:

Year:  1996        PMID: 8736222     DOI: 10.1016/0042-6989(95)00174-3

Source DB:  PubMed          Journal:  Vision Res        ISSN: 0042-6989            Impact factor:   1.886


  17 in total

1.  The electroretinogram recorded at the onset of dark-adaptation: understanding the origin of the scotopic oscillatory potentials.

Authors:  S Rousseau; P Lachapelle
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

2.  Comparison of conventional ERG parameters and high-intensity A-wave analysis in a clinical setting.

Authors:  Michael F Marmor; Alexandra Serrato; Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2003-05       Impact factor: 2.379

3.  A detailed phenotypic study of "cone dystrophy with supernormal rod ERG".

Authors:  M Michaelides; G E Holder; A R Webster; D M Hunt; A C Bird; F W Fitzke; J D Mollon; A T Moore
Journal:  Br J Ophthalmol       Date:  2005-03       Impact factor: 4.638

4.  Two-color pupillometry in KCNV2 retinopathy.

Authors:  Frederick T Collison; Jason C Park; Gerald A Fishman; Edwin M Stone; J Jason McAnany
Journal:  Doc Ophthalmol       Date:  2019-03-29       Impact factor: 2.379

5.  Phenotypic characteristics including in vivo cone photoreceptor mosaic in KCNV2-related "cone dystrophy with supernormal rod electroretinogram".

Authors:  Ajoy Vincent; Tom Wright; Yaiza Garcia-Sanchez; Marsha Kisilak; Melanie Campbell; Carol Westall; Elise Héon
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-01-30       Impact factor: 4.799

6.  Rod and cone a-waves in central retinal vein occlusion.

Authors:  Naoyuki Tanimoto; Tomoaki Usui; Mikio Ichibe; Mineo Takagi; Keiko Suzuki; Shigeru Hasegawa; Haruki Abe
Journal:  Jpn J Ophthalmol       Date:  2005 Sep-Oct       Impact factor: 2.447

7.  Mutations in the gene KCNV2 encoding a voltage-gated potassium channel subunit cause "cone dystrophy with supernormal rod electroretinogram" in humans.

Authors:  Huimin Wu; Jill A Cowing; Michel Michaelides; Susan E Wilkie; Glen Jeffery; Sharon A Jenkins; Viktoria Mester; Alan C Bird; Anthony G Robson; Graham E Holder; Anthony T Moore; David M Hunt; Andrew R Webster
Journal:  Am J Hum Genet       Date:  2006-07-24       Impact factor: 11.025

8.  Utility in clinical practice of standard vs. high-intensity ERG a-waves.

Authors:  Mira Marcus; Lorella Cabael; Michael F Marmor
Journal:  Doc Ophthalmol       Date:  2006-11       Impact factor: 2.379

9.  Retinal function and PKC alpha expression after focal laser photocoagulation.

Authors:  Karin Gjörloff Wallentén; Malin Malmsjö; Sten Andréasson; Angelica Wackenfors; Kristina Johansson; Fredrik Ghosh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-17       Impact factor: 3.117

10.  Rod and cone function in patients with KCNV2 retinopathy.

Authors:  Ditta Zobor; Susanne Kohl; Bernd Wissinger; Eberhart Zrenner; Herbert Jägle
Journal:  PLoS One       Date:  2012-10-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.